MNAR is significant because it can introduce substantial biases in clinical trial results, epidemiological studies, and patient outcome analyses. For instance, if patients with advanced stages of cancer are less likely to report their symptoms or participate in studies, the resulting data may underestimate the severity and progression of the disease.
